TY  - GEN
AU  - Timmerman,John
AU  - Herbaux,Charles
AU  - Ribrag,Vincent
AU  - Zelenetz,Andrew D
AU  - Houot,Roch
AU  - Neelapu,Sattva S
AU  - Logan,Theodore
AU  - Lossos,Izidore S
AU  - Urba,Walter
AU  - Salles,Gilles
AU  - Ramchandren,Radhakrishnan
AU  - Jacobson,Caron
AU  - Godwin,John
AU  - Carpio,Cecilia
AU  - Lathers,Deanne
AU  - Liu,Yali
AU  - Neely,Jaclyn
AU  - Suryawanshi,Satyendra
AU  - Koguchi,Yoshinobu
AU  - Levy,Ronald
TI  - Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma
SN  - 1096-8652
PY  - 2020///0603
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - pharmacokinetics
KW  - Antineoplastic Agents, Immunological
KW  - pharmacology
KW  - Female
KW  - Humans
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Progression-Free Survival
KW  - Rituximab
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/ajh.25757
ER  -